Skip to main content

Table 3 Demographics of study participants

From: Functional neuronal network activity differs with cognitive dysfunction in childhood-onset systemic lupus erythematosus

   cSLE without NCD (n= 14) cSLE with NCD (n= 7) P-value1
Age, years   14.7 ± 2.1 15.1 ± 1.9 NS
Female Number, % 11 (78.6%) 6 (85.7%) NS
Race/ethnicity White/black/hispanic/other 6/4/2/2 1/6/0/0 NS
Highest maternal educational level Postgraduate degree/Bachelor's degree/partial college or associate degree/High School degree/unknown 2/4/4/4/0 0/0/3/3/1 NS
WASI full scale IQ score   104.4 ± 10.5 89.0 ± 7.4 0.005
Annual family income (in "tabcaption",000)   84.4 ± 48.9 34.4 ± 17.3 0.003
Disease duration, years 2.5 ± 2.2 1.6 ± 1.6 NS
Medications Prednisone (mg/kg/day) 11.7 ± 7.4 16.9 ± 11.8 NS
  Treatment with immunosuppressant2 5 (35.7%) 5 (71.4%) NS
Disease activity and damage SLEDAI score 4.1 ± 3.0 7.1 ± 6.2 NS
  SDI score 0.4 ± 0.8 0.7 ± 1.1 NS
Imaging sites Site 1/site 2 10/4 6/1 NS
Neurocognitive dysfunction Average z-scores    
  Working memory -0.15 ± 0.52 -1.03 ± 0.59 0.0038
  Psychomotor speed 0.23 ± 0.69 -1.22 ± 0.38 0.0001
  Attention 0.13 ± 0.57 -0.39 ± 1.08 NS
  Visuoconstructional ability 0.30 ± 0.46 -1.22 ± 0.91 < 0.0001
  1. Values are means and SD unless indicated otherwise. 1P-values are based on t-tests or Fisher's exact test, when appropriate. 2Number of patients (without/with) neurocognitive dysfunction (NCD) treated with: mycophenolate mofetil (4/2); azathioprine (2/1); methotrexate (1/0); mycophenolate mofetil plus cyclophosphamide (0/1); cyclophosphamide (0/1). cSLE, childhood-onset systemic lupus erythematosus; WASI, Wechsler abbreviated scales of intelligence; NS, not significant; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index (2-k version; range 0 to 105; 0 = inactive disease); SDI: Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (range 0 to 46; 0 = no damage).